BNM-III-170

CAS No. 1859189-54-0

BNM-III-170( —— )

Catalog No. M12870 CAS No. 1859189-54-0

BNM-III-170 is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    BNM-III-170
  • Note
    Research use only, not for human use.
  • Brief Description
    BNM-III-170 is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.
  • Description
    BNM-III-170 is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo; binds the HIV-1 gp120 Env and promotes conformational changes similar to those induced by CD4, exposing conserved Env elements to antibodies; synergizes with antibodies elicited by monomeric HIV-1 gp120 to protect monkeys from multiple high-dose intrarectal challenges with a heterologous simian-human immunodeficiency virus (SHIV).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1859189-54-0
  • Formula Weight
    446.911
  • Molecular Formula
    C21H24ClFN6O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    N1-(4-chloro-3-fluorophenyl)-N2-((1R,2R)-2-(guanidinomethyl)-5-((methylamino)methyl)-2,3-dihydro-1H-inden-1-yl)oxalamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Madani N, et al. Nat Commun. 2018 Jun 18;9(1):2363.
molnova catalog
related products
  • (Iso)-Fosdevirine

    (Iso)-Fosdevirine ( (Iso)-GSK2248761) is a selective and potent non-nucleoside reverse transcriptase (NNRTI) inhibitor with anti-HIV activity for the study of neurological disorders such as late-onset epilepsy.

  • Decanoyl-RVKR-CMK

    Subtilisin/Kex2p-like proprotein convertase inhibitor; blocks activity of all seven convertases (PC1, PC2, PC4, PACE4, PC5, PC7 and furin). Abolishes proET-1 processing in endothelial cells; inhibits regulated secretion of the neuronal polypeptide VGF in PC12 cells.

  • Darunavir

    A potent, selective HIV-1 protease inhibitor that is extremely potent against laboratory HIV-1 strains and primary clinical isolates with IC50 of 3 nM, IC90 of 9 nM.